Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5405-5412

  Beyda, Nicholas D ^a   Liao, Guangling ^a   Endres, Bradley T ^a   Lewis, Russell E ^b   Garey, Kevin W ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE; ANTIFUNGAL AGENT; BETA GLUCAN; FUNGAL PROTEIN; LIPOPEPTIDE;

ANIMAL CELL; ANTIFUNGAL RESISTANCE; ARTICLE; BLOODSTREAM INFECTION; CANDIDA GLABRATA; CANDIDEMIA; CELL WALL; CLINICAL ARTICLE; CONTROLLED STUDY; FUNGUS ISOLATION; GENE MUTATION; HUMAN; IMMUNOPHARMACOLOGY; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE; ANIMAL; CELL LINE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; PATHOGENICITY;

ANIMALS; ANTIFUNGAL AGENTS; BETA-GLUCANS; CANDIDA GLABRATA; CANDIDEMIA; CELL LINE; ECHINOCANDINS; FUNGAL PROTEINS; HUMANS; IMMUNITY, INNATE; LIPOPEPTIDES; MICE; MICROBIAL SENSITIVITY TESTS; MUTATION; VORICONAZOLE;

EID: 84940910092     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00624-15     Document Type: Article

References (22)

1. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535. http://dx.doi.org /10.1086/596757.
2. Lewis RE, Liao G, Young K, Douglas C, Kontoyiannis DP. 2014.Macrophage reporter cell assay for screening immunopharmacological activity of cell wall-active antifungals. Antimicrob Agents Chemother 58: 1738-1743. http://dx.doi.org/10.1128/AAC.02408-13.
3. Wheeler RT, Kombe D, Agarwala SD, Fink GR. 2008. Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment. PLoS Pathog 4:e1000227. http://dx.doi.org/10.1371 /journal.ppat.1000227.
4. Wheeler RT, Fink GR. 2006. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2:e35. http://dx.doi.org/10 .1371/journal.ppat.0020035.
5. Hohl TM, Feldmesser M, Perlin DS, Pamer EG. 2008. Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J Infect Dis 198: 176-185. http://dx.doi.org/10.1086/589304.
6. Chen SC-A, Slavin MA, Sorrell TC. 2011. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71:11-41. http://dx.doi.org/10 .2165/11585270-000000000-00000.
7. Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S, Du C, Clancy CJ. 2012. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother 56:4862-4869. http://dx.doi.org/10.1128/AAC.00027-12.
8. Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW. 2014. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis 59:819-825. http://dx.doi.org/10.1093/cid/ciu407.
9. Brunke S, Seider K, Fischer D, Jacobsen ID, Kasper L, Jablonowski N, Wartenberg A, Bader O, Enache-Angoulvant A, Schaller M, d'Enfert C, Hube B. 2014. One small step for a yeast-microevolution within macrophages renders Candida glabrata hypervirulent due to a single point mutation. PLoS Pathog 10:e1004478. http://dx.doi.org/10.1371/journal.ppat .1004478.
10. Rai MN, Balusu S, Gorityala N, Dandu L, Kaur R. 2012. Functional genomic analysis of Candida glabrata-macrophage interaction: role of chromatin remodeling in virulence. PLoS Pathog 8:e1002863. http://dx .doi.org/10.1371/journal.ppat.1002863.
11. Lewis RE, Viale P, Kontoyiannis DP. 2012. The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida. Virulence 3:368-376. http://dx.doi.org/10.4161/viru.20746.
12. Seider K, Brunke S, Schild L, Jablonowski N, Wilson D, Majer O, Barz D, Haas A, Kuchler K, Schaller M, Hube B. 2011. The facultative intracellular pathogen Candida glabrata subverts macrophage cytokine production and phagolysosome maturation. J Immunol 187:3072-3086. http://dx.doi.org/10.4049/jimmunol.1003730.
13. Beyda ND, Lewis RE, Garey KW. 2012. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother 46:1086-1096. http://dx.doi.org/10.1345 /aph.1R020.
14. Ben-Ami R, Garcia-Effron G, Lewis RE, Gamarra S, Leventakos K, Perlin DS, Kontoyiannis DP. 2011. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis 204:626-635. http://dx.doi.org/10.1093/infdis/jir351.
15. Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller T, Lockhart SR. 2010. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother 54:5042-5047. http://dx.doi.org /10.1128/AAC.00836-10.
16. Romani L. 2011. Immunity to fungal infections. Nat Rev Immunol 11: 275-288. http://dx.doi.org/10.1038/nri2939.
17. Baltch AL, Lawrence DA, Ritz WJ, Andersen NJ, Bopp LH, Michelsen PB, Carlyn CJ, Smith RP. 2012. Effects of echinocandins on cytokine/ chemokine production by human monocytes activated by infection with Candida glabrata or by lipopolysaccharide. Diagn Microbiol Infect Dis 72:226-233. http://dx.doi.org/10.1016/j.diagmicrobio.2011.11.004.
18. Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Lasseter KC. 2004. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 48:815-823. http://dx.doi.org/10.1128/AAC.48.3.815-823.2004.
19. Undre NA, Stevenson P, Freire A, Arrieta A. 2012. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia. Pediatr Infect Dis J 31:630- 632. http://dx.doi.org/10.1097/INF .0b013e31824ab9b0.
20. Walker LA, Gow NA, Munro CA. 2013. Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob Agents Chemother 57:146-154. http://dx.doi.org/10.1128/AAC.01486-12.
21. Goins TL, Cutler JE. 2000. Relative abundance of oligosaccharides in Candida species as determined by fluorophore-assisted carbohydrate electrophoresis. J Clin Microbiol 38:2862-2869.
22. Koul A, Vitullo J, Reyes G, Ghannoum M. 1999. Effects of voriconazole on Candida glabrata in vitro. J Antimicrob Chemother 44:109-112. http: //dx.doi.org/10.1093/jac/44.1.109.